|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Youlden DR, Cramb SM, Dunn NA, Muller JM,
Pyke CM and Baade PD: The descriptive epidemiology of female breast
cancer: An international comparison of screening, incidence,
survival and mortality. Cancer Epidemiol. 36:237–248. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruvkun G: Clarifications on miRNA and
cancer. Science. 311:36–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xi Y, Shalgi R, Fodstad O, Pilpel Y and Ju
J: Differentially regulated micro-RNAs and actively translated
messenger RNA transcripts by tumor suppressor p53 in colon cancer.
Clin Cancer Res. 12:2014–2024. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira
M, Matsumoto H and Horiguchi J: Recent trends in microRNA research
into breast cancer with particular focus on the associations
between microRNAs and intrinsic subtypes. J Hum Genet. 62:15–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kayani M, Kayani MA, Malik FA and Faryal
R: Role of miRNAs in breast cancer. Asian Pac J Cancer Prev.
12:3175–3180. 2011.PubMed/NCBI
|
|
11
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Serpico D, Molino L and Di Cosimo S:
microRNAs in breast cancer development and treatment. Cancer Treat
Rev. 40:595–604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takahashi Ru, Miyazaki H and Ochiya T: The
roles of microRNAs in breast cancer. Cancers (Basel). 7:598–616.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim LP, Lim LP, Glasner ME, Yekta S, Burge
CB and Bartel DP: Vertebrate microRNA genes. Science. 299:15402003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pichiorri F, Suh SS, Rocci A, De Luca L,
Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder
H, et al: Downregulation of p53-inducible microRNAs 192, 194, and
215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma
development. Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schotte D, De Menezes RX, Akbari Moqadam
F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R and Den
Boer ML: MicroRNA characterize genetic diversity and drug
resistance in pediatric acute lymphoblastic leukemia.
Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Feinberg-Gorenshtein G, Guedj A, Shichrur
K, Jeison M, Luria D, Kodman Y, Ash S, Feinmesser M, Edry L,
Shomron N, et al: MiR-192 directly binds and regulates Dicer1
expression in neuroblastoma. PLoS One. 8:e787132013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song B, Wang Y, Kudo K, Gavin EJ, Xi Y and
Ju J: miR-192 Regulates dihydrofolate reductase and cellular
proliferation through the p53-microRNA circuit. Clin Cancer Res.
14:8080–8068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X,
Zhou X and Gan J: A serum microRNA panel as potential biomarkers
for hepatocellular carcinoma related with hepatitis B virus. PLoS
One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal
R, Mori Y, Olaru AV, Yang J, David S, Hamilton JP, et al:
MicroRNA-192 and-215 are upregulated in human gastric cancer in
vivo and suppress ALCAM expression in vitro. Oncogene.
30:1577–1585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Augello C, Vaira V, Caruso L, Destro A,
Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M and
Bosari S: MicroRNA profiling of hepatocarcinogenesis identifies
C19MC cluster as a novel prognostic biomarker in hepatocellular
carcinoma. Liver Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin Y, Lu J, Wen J, Shen Y and Wen X:
Regulation of growth of human bladder cancer by miR-192. Tumor
Biol. 36:3791–3797. 2015. View Article : Google Scholar
|
|
25
|
Xu YJ and Fan Y: MiR-215/192 participates
in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun J, Fan Z, Lu S, Yang J, Hao T and Huo
Q: MiR-192 suppresses the tumorigenicity of prostate cancer cells
by targeting and inhibiting nin one binding protein. Int J Mol Med.
37:485–492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng S, Cong S, Zhang X, Bao X, Wang W, Li
H, Wang Z, Wang G, Xu J, Du B, et al: MicroRNA-192 targeting
retinoblastoma 1 inhibits cell proliferation and induces cell
apoptosis in lung cancer cells. Nucleic Acids Res. 39:6669–6678.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gupta R, Toufaily C and Annabi B: Caveolin
and cavin family members: Dual roles in cancer. Biochimie.
107:188–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burgermeister E, Liscovitch M, Röcken C,
Schmid RM and Ebert MP: Caveats of caveolin-1 in cancer
progression. Cancer Lett. 268:187–201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Wang N, Liu P, Peng F, Tang H,
Chen Q, Xu R, Dai Y, Lin Y, Xie X, et al: Caveolin-1, a
stress-related oncotarget, in drug resistance. Oncotarget.
6:37135–37150. 2015.PubMed/NCBI
|
|
31
|
Patani N, Martin LA, Reis-Filho JS and
Dowsett M: The role of caveolin-1 in human breast cancer. Breast
Cancer Res Treat. 131:1–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Savage K, Lambros MB, Robertson D, Jones
RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F,
et al: Caveolin 1 is overexpressed and amplified in a subset of
basal-like and metaplastic breast carcinomas: A morphologic,
ultrastructural, immunohistochemical, and in situ hybridization
analysis. Clin Cancer Res. 13:90–101. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang SF, Yang JY, Huang CH, Wang SN, Lu
CP, Tsai CJ, Chai CY and Yeh YT: Increased caveolin-1 expression
associated with prolonged overall survival rate in hepatocellular
carcinoma. Pathology. 42:438–445. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chatterjee M, Ben-Josef E, Thomas DG,
Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA,
Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor
progression and confers a multi-modality resistance phenotype in
pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar : PubMed/NCBI
|
